Literature DB >> 3584716

Vasoconstrictor activity of coronary sinus plasma from patients with coronary artery disease.

G M Rubanyl, R L Frye, D R Holmes, P M Vanhoutte.   

Abstract

Vasoactive properties of plasma samples taken from the coronary sinus, a systemic artery and the superior vena cava of 13 patients with angiographically proven coronary artery disease and from 5 patients with normal coronary arteriograms were assayed in vitro by measurement of the changes in tension of rings of isolated canine coronary arteries. Addition of 1 ml samples of platelet-rich plasma from the coronary sinus of patients with coronary artery disease into a 20 ml organ bath induced an initial relaxation followed by sustained constriction in bioassay coronary artery rings with endothelium and only vasoconstriction in rings without endothelium. The vasoconstrictor activity of the coronary sinus plasma showed positive correlation with the severity and extent of coronary artery narrowing. Systemic arterial and venous plasma samples from patients with coronary artery disease and the coronary sinus plasma from patients with no coronary artery disease evoked only endothelium-dependent relaxations. These vasoactive properties of the various plasma samples were similar whether the samples were taken during rest or during supine bicycle exercise. The serotoninergic receptor antagonist methiothepin prevented the vasoconstriction induced by the coronary sinus plasma samples. These data demonstrate that the coronary sinus blood of patients with atheromatous coronary artery disease exhibits vasoconstrictor activity that may be associated with 5-hydroxytryptamine (serotonin), presumably released from platelets.

Entities:  

Mesh:

Year:  1987        PMID: 3584716     DOI: 10.1016/s0735-1097(87)80462-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

1.  Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane.

Authors:  A Maassen VanDenBrink; W A Bax; M D Ferrari; F J Zijlstra; E Bos; P R Saxena
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 2.  Calcium antagonists in myocardial ischemia/reperfusion--update 2012.

Authors:  Petra Kleinbongard; Theodor Baars; Gerd Heusch
Journal:  Wien Med Wochenschr       Date:  2012-06-14

3.  Cardiac release of chemoattractants after ischaemia induced by coronary balloon angioplasty.

Authors:  F J Neumann; G Richardt; M Schneider; I Ott; H M Haupt; H Tillmanns; A Schömig; B Rauch
Journal:  Br Heart J       Date:  1993-07

4.  Should all patients with risk factors for ischemic heart disease receive aspirin?

Authors:  J T Willerson; S D Mueller; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1992

5.  Unstable angina pectoris and the progression to acute myocardial infarction. Role of platelets and platelet-derived mediators.

Authors:  J T Willerson; S K Yao; J J Ferguson; H V Anderson; P Golino; L M Buja
Journal:  Tex Heart Inst J       Date:  1991

6.  Potential of combined thromboxane A2 and serotonin antagonists to prevent the development of unstable angina and acute myocardial infarction.

Authors:  J T Willerson; L M Buja
Journal:  Tex Heart Inst J       Date:  1990

7.  Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions.

Authors:  K Egashira; T Inou; Y Hirooka; A Yamada; Y Maruoka; H Kai; M Sugimachi; S Suzuki; A Takeshita
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

8.  Analysis of Serotonin Molecules on Silver Nanocolloids-A Raman Computational and Experimental Study.

Authors:  Felicia S Manciu; John D Ciubuc; Emma M Sundin; Chao Qiu; Kevin E Bennet
Journal:  Sensors (Basel)       Date:  2017-06-22       Impact factor: 3.576

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.